GlassScriptPhysician profile
Aimee Foord
NPI 1821312844
$41,071.83
in general payments reported to CMS, 2019-2025
32 companies · $24K in 2025
The $24K reported for 2025 was more than what 92% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $621 · 2023: $998 · 2024: $15K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,200 · Travel and Lodging: $4,342 · Food and Beverage: $3,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,659.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,200.00 |
| Travel and Lodging | $4,342.10 |
| Food and Beverage | $3,249.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17,072.50 | 2022-2025 | |
| Sobi, INC | $7,911.38 | 2024-2025 | |
| Csl Behring | $5,924.90 | 2023-2025 | Hemgenix |
| Hema Biologics, LLC | $3,025.00 | 2024 | Sevenfact |
| Pfizer INC. | $2,673.12 | 2023-2024 | |
| Novo Nordisk INC | $2,179.97 | 2022-2025 | Alhemo |
| Octapharma USA, INC. | $355.87 | 2023-2025 | Nuwiq, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $276.95 | 2022-2023 | |
| Pharming Healthcare, INC. | $268.73 | 2023-2025 | Joenja, Ruconest |
| Kedrion Biopharma, INC. | $214.55 | 2023-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Bio Products Laboratory USA, INC. | $141.06 | 2022-2023 | Gammaplex, Coagadex |
| Emmaus Medical, INC. | $137.02 | 2022 | |
| Spark Therapeutics, INC. | $124.97 | 2023 | |
| Janssen Scientific Affairs, LLC | $115.14 | 2023 | Xarelto |
| Genentech USA, INC. | $101.65 | 2022-2024 | Hemlibra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $71.61 | 2024-2025 | Elfabrio |
| Takeda Pharmaceuticals U.S.A., INC. | $60.47 | 2023-2025 | Advate, Vpriv |
| Adaptive Biotechnologies Corporation | $55.46 | 2024-2025 | Clonoseq |
| Incyte Corporation | $41.42 | 2025 | Jakafi, Niktimvo |
| Jazz Pharmaceuticals INC. | $39.09 | 2024 | |
| Genetix Biotherapeutics INC | $37.48 | 2023-2025 | Lyfgenia |
| Pharmacosmos Therapeutics INC. | $34.86 | 2024 | Monoferric |
| Uswm, LLC | $31.16 | 2025 | Iwilfin |
| Syndax Pharmaceuticals, INC. | $28.66 | 2025 | |
| Biogen, INC. | $28.22 | 2025 | Spinraza |
| Novartis Pharmaceuticals Corporation | $27.55 | 2025 | |
| Biomarin Pharmaceutical INC. | $25.20 | 2024 | Roctavian |
| Servier Pharmaceuticals LLC | $24.71 | 2024 | |
| Apellis Pharmaceuticals, INC. | $23.95 | 2024 | Empaveli |
| Rare Disease Therapeutics, INC. | $19.18 | 2024 | Purixan |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Foord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.